Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.
Two-thirds of the world's HIV-infected people live in sub-Saharan Africa, and more than 1.5 million of them die annually. As access to antiretroviral treatment has expanded within the region; early pessimism concerning the delivery of antiretroviral treatment using a large-scale public health approach has, at least in the short term, proved to be broadly unfounded. Immunological and virological responses to ART are similar to responses in patients treated in high-income countries. Despite this, however, early mortality rates in sub-Saharan Africa are very high; between 8 and 26% of patients die in the first year of antiretroviral treatment, with most deaths occurring in the first few months. Patients typically access antiretroviral treatment with advanced symptomatic disease, and mortality is strongly associated with baseline CD4 cell count less than 50 cells/mul and WHO stage 4 disease (AIDS). Although data are limited, leading causes of death appear to be tuberculosis, acute sepsis, cryptococcal meningitis, malignancy and wasting syndrome. Mortality rates are likely to depend not only on the care delivered by antiretroviral treatment programmes, but more fundamentally on how advanced disease is at programme enrollment and the quality of preceding healthcare. In addition to improving delivery of antiretroviral treatment and providing it free of charge to the patient, strategies to reduce mortality must include earlier diagnosis of HIV infection, strengthening of longitudinal HIV care and timely initiation of antiretroviral treatment. Health systems delays in antiretroviral treatment initiation must be minimized, especially in patients who present with advanced immunodeficiency.
Lawn
Stephen D
SD
Harries
Anthony D
AD
Anglaret
Xavier
X
Myer
Landon
L
Wood
Robin
R
D017954:Africa South of the Sahara / Q000453:epidemiology; D023241:Antiretroviral Therapy, Highly Active; D002423:Cause of Death; D003695:Delivery of Health Care / Q000458:organization & administration; D042241:Early Diagnosis; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D012307:Risk Factors
Lancet. 2006 Jun 17;367(9527):1981-9
16782488
Lancet. 2002 Jul 13;360(9327):119-29
12126821
Arch Intern Med. 2008 Jan 14;168(1):86-93
18195200
Lancet. 2006 Mar 11;367(9513):817-24
16530575
N Engl J Med. 2006 Sep 14;355(11):1141-53
16971720
Clin Infect Dis. 2006 Sep 15;43(6):770-6
16912954
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Lancet. 2003 Jul 5;362(9377):22-9
12853195
IAPAC Mon. 2002 Jun;8(6):168-75
12154788
AIDS. 2007 Jul 11;21(11):1441-8
17589190
J Infect Dis. 2007 Aug 15;196 Suppl 1:S52-62
17624827
BMC Infect Dis. 2006 Mar 21;6:59
16551345
Int J Tuberc Lung Dis. 2007 Aug;11(8):848-53
17705949
Clin Infect Dis. 2006 Oct 15;43(8):1069-73
16983622
Clin Infect Dis. 2005 Jul 15;41(2):217-24
15983918
S Afr Med J. 2006 Apr;96(4):315-20
16670804
Bull World Health Organ. 2007 Jul;85(7):550-4
17768504
Antivir Ther. 2007;12(5):753-60
17713158
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jan 1;14(1):83-5
8989219
Int J Tuberc Lung Dis. 2007 Apr;11(4):412-6
17394687
AIDS. 2003 Jul;17 Suppl 3:S5-15
14565604
AIDS. 2006 May 12;20(8):1181-9
16691070
PLoS Med. 2007 Oct 16;4(10):e298
17941716
Clin Infect Dis. 2002 Dec 15;35(12):e128-33
12471589
Trop Med Int Health. 2007 Aug;12(8):929-35
17697087
N Engl J Med. 1998 Mar 26;338(13):853-60
9516219
AIDS. 2005 Nov 18;19(17):2050-2
16260920
J Infect. 2006 Dec;53(6):357-63
16487593
AIDS. 2005 Jul 1;19(10):1043-9
15958835
Antivir Ther. 2005;10(5):615-24
16152755
Am J Respir Crit Care Med. 2007 Jan 1;175(1):87-93
16973982
Arch Intern Med. 2003 Oct 13;163(18):2187-95
14557216
AIDS. 2007 Mar 30;21(6):713-9
17413692
S Afr Med J. 2006 Aug;96(8):722-4
17019496
AIDS. 2007 Nov 30;21(18):2483-91
18025885
J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):14-7
15608518
AIDS. 2004 Apr 9;18(6):887-95
15060436
Lancet. 2006 Apr 15;367(9518):1256-61
16631881
PLoS Med. 2006 Jan;3(1):e4
16318413
Clin Infect Dis. 2007 Jul 1;45(1):76-80
17554704
Bull World Health Organ. 2004 May;82(5):354-63
15298226
J Infect Dis. 2005 Mar 15;191(6):825-9
15717255
AIDS. 1993 Dec;7(12):1569-79
7904450
AIDS. 2005 Dec 2;19(18):2141-8
16284464
AIDS. 2004 May 21;18(8):1159-68
15166531
Lancet. 2002 Jul 6;360(9326):34-40
12114039
AIDS. 2007 Jan 2;21(1):121-2
17148984
J Acquir Immune Defic Syndr. 2006 May;42(1):29-35
16763490
Lancet. 2006 Apr 22;367(9519):1335-42
16631912
AIDS. 2002 Jan 4;16(1):75-83
11741165
AIDS. 2007 Jun 19;21(10):1301-8
17545706
JAMA. 2006 Aug 16;296(7):782-93
16905784
BMJ. 1994 Jun 11;308(6943):1531-3
7912597
AIDS. 2006 Nov 28;20(18):2355-60
17117022
AIDS. 2008 Apr 23;22(7):873-82
18427206
AIDS. 2005 Aug 12;19(12):1243-9
16052078
J Adv Nurs. 2006 Apr;54(1):132
16553698
AIDS. 2007 Jan 30;21(3):335-41
17255740
Clin Infect Dis. 2005 May 15;40(10):1500-7
15844073
J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):320-3
15076249
J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):20-6
12352146
J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84
16878045
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):121-3; author reply 123
17909319
AIDS. 2006 Aug 1;20(12):1605-12
16868441
Lancet. 2006 Jun 3;367(9525):1870-2
16753490
Antivir Ther. 2003 Oct;8(5):385-93
14640385
Lancet Infect Dis. 2005 Jun;5(6):361-73
15919622
East Afr Med J. 1996 May;73(5 Suppl):S7-8
8756018
J Infect Dis. 2007 Aug 15;196 Suppl 1:S46-51
17624825
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):336-43
16249709
S Afr Med J. 2007 Jun;97(6):412, 414-5
17691468
AIDS. 2003 Jun 13;17(9):1369-75
12799558
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):56-61
17972365
J Infect Dis. 2004 Nov 1;190(9):1670-6
15478074
AIDS. 2003 Mar 7;17(4):575-84
12598778
BMC Infect Dis. 2006 Sep 01;6:136
16948852
Antivir Ther. 2006;11(1):63-72
16518961
Lancet. 2006 Oct 7;368(9543):1254-9
17027731
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):626-31
16044018